ReviewFrontiers in immunology2026
Multidimensional exploration of the relationship between gut microbiota and colorectal cancer: focus on clinical tumorigenesis and treatment.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota has received considerable attention in the field of colorectal cancer (CRC) research in recent years. In this review, we have explored the multifaceted relationship between the gut microbiota and CRC progression and treatment. The composition, distribution, and normal physiological functions of the gut microbiota have been summarized, along with the association between gut dysbiosis and CRC based on the body of evidence from animal experiments and clinical studies. In addition, we have discussed the mechanisms through which specific microbial configurations or microbiota-derived metabolites may contribute to colorectal carcinogenesis, including genotoxic effects, inflammation, and immune dysregulation. The impact of the gut microbiota on the efficacy of chemotherapy, radiotherapy, and immunotherapy, and new treatment strategies based on the gut microbiota, such as probiotic intervention, prebiotic application, and fecal microbiota transplantation have also been explored. Despite some promising outcomes, the specific carcinogenic microorganisms have not been identified, and it is challenging to distinguish association from causation, determine the influence of individual differences, and translate the research to clinical applications. In the future, more rigorous longitudinal studies, gnotobiotic models with defined microbial communities, and mechanistic interventional studies are needed to strengthen causal inference, and provide practical guidance for CRC prevention and treatment. Beyond summarizing reported associations, this review proposes a microbiota-immune-metabolism-therapy axis by integrating tumorigenic mechanisms, immune contexture, and treatment responsiveness into a single translational framework.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.